Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2011
Metadata
Show full item recordAbstract
The purine ribonucleoside adenosine (Ado) has been recognized for its regulatory functions in situations of cellular stress like ischemia, hypoxia and inflammation. The importance of extracellular Ado as a modulator in the immune system is a theme of great appreciation and the focus of recent increasing interest in the field of gastrointestinal inflammation. In this review, the different aspects of Ado signaling during inflammatory responses in the gut are discussed, considering the contribution of the four known Ado receptors (ARs; A(1), A(2A), A(2B), and A(3)), their mechanisms and expression patterns. Activation of these receptors in epithelial cells as well as in immune cells recruited to the inflamed intestinal mucosa determines the overall effect, ranging from a protective, anti-inflammatory modulation to a strong pro-inflammatory induction. Here we present the current advances in agonists and antagonists development and their potential therapeutic application studied in animal models of intestinal inflammation. In addition, alternative complementary approaches to manipulate such a complex signaling system are discussed, for example, the use of AR allosteric modulators or interference with Ado metabolism. Special features of the gut environment are taken into account: the contribution of diet components; the involvement of Ado in intestinal infections; the interactions with the gut microbiome, particularly, the recent exciting finding that an intestinal bacterium can directly produce extracellular Ado in response to host defense mechanisms in an inflammation scenario. Understanding each component of this dynamic system will broaden the possibilities for applying Ado signaling as a therapeutic target in gut inflammation.Citation
Adenosine in the inflamed gut: a Janus faced compound. 2011, 18 (18):2791-815 Curr. Med. Chem.Affiliation
Helmholtz Center for Infection Research, Chemical Microbiology, Inhoffenstrasse 7, 38124 Braunschweig, Germany.Journal
Current medicinal chemistryPubMed ID
21649583Language
enISSN
1875-533XThe following license files are associated with this item:
Related articles
- Adenosine, adenosine receptors and myocardial protection: an updated overview.
- Authors: Mubagwa K, Flameng W
- Issue date: 2001 Oct
- Stimulation of chloride secretion by P1 purinoceptor agonists in cystic fibrosis phenotype airway epithelial cell line CFPEo-.
- Authors: Chao AC, Zifferblatt JB, Wagner JA, Dong YJ, Gruenert DC, Gardner P
- Issue date: 1994 May
- A(1) and A(3) adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes.
- Authors: Gessi S, Merighi S, Stefanelli A, Fazzi D, Varani K, Borea PA
- Issue date: 2013 Oct
- Anti-adrenergic effect of adenosine on Na(+)-Ca(2+) exchange current recorded from guinea-pig ventricular myocytes.
- Authors: Zhang YH, Hinde AK, Hancox JC
- Issue date: 2001 May
- Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases.
- Authors: Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Del Tacca M, Blandizzi C
- Issue date: 2008 Apr